Compass Bio - CMPX Net earnings per share for the last four quarters
The immuno-oncology industry relies on external contractors to conduct tests, which minimizes operational disruptions for Compass Therapeutics (CMPX). Compass Therapeutics (CMPX) creates unique bispecific antibodies for a dual strike on tumors, attracting top developers through a flexible culture and stock options. Measuring the annual EPS TTM growth visualizes profit dynamics, where the value 10.30 describes the current level of earnings per share.
CMPX (Compass Bio): analytical breakdowns and indicator data
- current price and projected stock value:
- issuer market value details:
- book value of equity indicators:
- debt and liquidity data:
Total Debt to Capital Compass Therapeutics|CMPX - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Compass Therapeutics Corp|CMPX - Company Debts|Debts to Book Value Compass Therapeutics Inc|CMPX - Company Long-Term Liabilities|Short-Term Indebtedness Compass Therapeutics|Intermediate Liquidity Ratio compasstherapeutics.com
- earnings and market multiples details:
CMPX - Net Profit|Expected Net Income Compass Therapeutics|CMPX - P/E Multiple|Projected Price to Earnings Ratio Compass Therapeutics Inc|CMPX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Compass Therapeutics Inc|CMPX - Operating profit EBITDA|Net earnings per share (EPS TTM) Compass Therapeutics|CMPX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months compasstherapeutics.com|CMPX - Net earnings per share growth this year|Expected net earnings per share growth next year Compass Therapeutics
Initial company analysis:CMPX, compasstherapeutics.com
Institutional capital evaluates Compass Therapeutics (CMPX) through the lens of R&D expenditures, as the absence of commercial sales renders traditional profit secondary. This annual percentage change in earnings per share (ttm) measures net income dynamics over 12 months, transforming quarterly reports into a continuous trend, which, given the company's lack of pricing power, turns this chart into an indicator of capital burn efficiency.
Direct competitors
Earnings per share for the trailing year IBRX (immunitybio.com)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Arcus Bio|Net earnings per share for the last 12 months Zymeworks Biopharmaceuticals (ZYME)|Earnings per share for the last twelve months Tango Therapeutics (TNGX)|Net earnings per share for the last 12 months iovance.com IOVA|Immatics - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc XNCR|REPL - Earnings per share for the last twelve months|LYEL (Lyell Pharma) - Earnings per share for the last 12 months|Innate Pharma S.A. (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics, Inc.)|Earnings per share for the trailing year IMMX|ALX Oncology Holdings - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cuebiopharma.com|pdsbiotech.com (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings - Earnings per share for the trailing year|MAIA (MAIA Biotechnology) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) liminatuspharma.com|Earnings per share for the last twelve months LAVA Therapeutics N.V. (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Therapeutics Inc (INTS) - Net earnings per one share for the last twelve months|Sensei Bio - Net earnings per share (EPS TTM)|therivabio.com (TOVX) - Net earnings per share for the last 12 months|gritstonebio.com (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta Inc (KA)|Earnings per share for the last twelve months NexImmune Corp|Net earnings per share for the last 12 months Turnstone Biologics Corporation (TSBX)|Earnings per share for the last twelve months Vaccinex, Inc. (VCNX)|HARP: Earnings per one share for the last 12 months
